132 related articles for article (PubMed ID: 29242101)
1. Epigenetic silencing of EVL/miR-342 in multiple myeloma.
Li Z; Wong KY; Chan GC; Chng WJ; Chim CS
Transl Res; 2018 Feb; 192():46-53. PubMed ID: 29242101
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of LPP/miR-28 in multiple myeloma.
Li Z; Wong KY; Chan GC; Chim CS
J Clin Pathol; 2018 Mar; 71(3):253-258. PubMed ID: 28775176
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.
Li Z; Wong KY; Calin GA; Chng WJ; Chan GC; Chim CS
Clin Epigenetics; 2019 May; 11(1):71. PubMed ID: 31064412
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy.
Zhang MY; Calin GA; Yuen KS; Jin DY; Chim CS
Clin Epigenetics; 2020 Oct; 12(1):150. PubMed ID: 33076962
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic silencing of MIR203 in multiple myeloma.
Wong KY; Liang R; So CC; Jin DY; Costello JF; Chim CS
Br J Haematol; 2011 Sep; 154(5):569-78. PubMed ID: 21707582
[TBL] [Abstract][Full Text] [Related]
6. Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification.
Wang LQ; Kumar S; Calin GA; Li Z; Chim CS
Br J Haematol; 2020 Jul; 190(2):249-261. PubMed ID: 32079038
[TBL] [Abstract][Full Text] [Related]
7. Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
Zhang Q; Wang LQ; Wong KY; Li ZY; Chim CS
J Clin Pathol; 2015 Jul; 68(7):557-61. PubMed ID: 25855800
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
Tatekawa S; Chinen Y; Ri M; Narita T; Shimura Y; Matsumura-Kimoto Y; Tsukamoto T; Kobayashi T; Kawata E; Uoshima N; Taki T; Taniwaki M; Handa H; Iida S; Kuroda J
Br J Haematol; 2017 Aug; 178(4):534-546. PubMed ID: 28439875
[TBL] [Abstract][Full Text] [Related]
9. miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration.
Zhang MY; Wang LQ; Chim CS
Cell Commun Signal; 2021 May; 19(1):62. PubMed ID: 34044822
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.
Grady WM; Parkin RK; Mitchell PS; Lee JH; Kim YH; Tsuchiya KD; Washington MK; Paraskeva C; Willson JK; Kaz AM; Kroh EM; Allen A; Fritz BR; Markowitz SD; Tewari M
Oncogene; 2008 Jun; 27(27):3880-8. PubMed ID: 18264139
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
12. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma.
Krzeminski P; Sarasquete ME; Misiewicz-Krzeminska I; Corral R; Corchete LA; Martín AA; García-Sanz R; San Miguel JF; Gutiérrez NC
Biochim Biophys Acta; 2015 Mar; 1849(3):353-66. PubMed ID: 25497370
[TBL] [Abstract][Full Text] [Related]
13. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the MIR129-2 in hematological malignancies.
Wong KY; Yim RL; Kwong YL; Leung CY; Hui PK; Cheung F; Liang R; Jin DY; Chim CS
J Hematol Oncol; 2013 Feb; 6():16. PubMed ID: 23406679
[TBL] [Abstract][Full Text] [Related]
15. RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNFα in the microenvironment.
Yuan L; Chan GC; Fung KL; Chim CS
Biochim Biophys Acta; 2014 Sep; 1843(9):1834-8. PubMed ID: 24875904
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of the miR-124-1 in haematological malignancies.
Wong KY; So CC; Loong F; Chung LP; Lam WW; Liang R; Li GK; Jin DY; Chim CS
PLoS One; 2011 Apr; 6(4):e19027. PubMed ID: 21544199
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.
Wang LQ; Kwong YL; Kho CS; Wong KF; Wong KY; Ferracin M; Calin GA; Chim CS
Mol Cancer; 2013 Dec; 12():173. PubMed ID: 24373626
[TBL] [Abstract][Full Text] [Related]
19. [Aberrant micro RNA and epigenetic network are associated with progression from MGUS to multiple myeloma].
Handa H
Rinsho Ketsueki; 2015 Aug; 56(8):981-8. PubMed ID: 26345556
[TBL] [Abstract][Full Text] [Related]
20. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.
Shimizu T; Suzuki H; Nojima M; Kitamura H; Yamamoto E; Maruyama R; Ashida M; Hatahira T; Kai M; Masumori N; Tokino T; Imai K; Tsukamoto T; Toyota M
Eur Urol; 2013 Jun; 63(6):1091-100. PubMed ID: 23200812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
